Dianthus Therapeutics, Inc. (DNTH) Research

Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.

Market snapshot

Symbol
DNTH
Price
$82.49
Day change
+0.73%
Market cap
$3.4B
P/E ratio
-349.93x
52-week range
16.64-96.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$115

Recent news

  • Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

    Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • Atai Beckley Inc. (ATAI)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Enliven Therapeutics, Inc. (ELVN)
  • Immatics N.V. (IMTX)
  • Nektar Therapeutics (NKTR)
  • Oculis Holding AG (OCS)
  • Sana Biotechnology, Inc. (SANA)

Recent insider activity

  • Veness Adam M — M-Exempt (30000 shares) on 2026-06-17
  • Veness Adam M — M-Exempt (30000 shares) on 2026-06-17
  • Veness Adam M — S-Sale (16771 shares) on 2026-06-17
  • Veness Adam M — S-Sale (13229 shares) on 2026-06-17
  • Randhawa Simrat — M-Exempt (9375 shares) on 2026-06-01

Open Dianthus Therapeutics, Inc. (DNTH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.